Highlights of Contemporary Genetically Altered Models may be contributed or invited and is meant to acquaint toxicologic pathologists with important biological and morphological features of newly established transgenic, knock-out, and related genetically engineered animal models. Although these Highlights will be based upon previously published papers, submissions will be peer reviewed. Suggested format includes background; experimental approach; biological, clinical, and pathologic (lesions, pathogenesis, and histomorphology) features; applications and implications.
INTRODUCTION
Xeroderma pigmentosum (XP) is an autosomal recessive disease of humans in which there is a defective nuzleotide-excision DNA repair gene. The disease is characterized by extreme sensitivity to sun exposure, a high incidence of skin cancer, and frequent neurological abnormalities. Patients with XP have a 1,000-fold increase in risk of skin cancer on sun-exposed (ultraviolet light, UV) areas of the body. The XP gene located on human chromosome 9 consists of 8 complementation groups, designated A through G and a variant. Damage to any number of the different complementation groups can result in XP; Group C is one of the most common forms of the disease (5) . The XPA gene and its promoter consist of approximately 2,700 base pairs and encode for the XPA protein. The protein is a zinc metalloprotein consisting of 273 amino acids that binds preferentially to UV-irradiated or chemical-carcinogen-damaged DNA. XPA binds to DNA, with a preference for damaged base pairs (3) . During nucleotide-excision repair, damaged DNA is incised on both sides of a lesion and an oligomer containing the damage is excised and replaced by repair DNA synthesis. In one group of XPA patients, the mutant protein, of which the cysteine-103 residue in the zinc finger motif was replaced with serine, has a vastly different protein conformation resulting in a loss of XPAcorrecting and DNA-binding activities (1) . XPC activity is part of a protein complex with single-stranded DNAbinding activity. Naturally occurring animal models of xeroderma pigmentosum Group A have not been described ; therefore, a transgenic mouse model would prove useful in research of this condition in humans. Two consecutive articles appearing in Nature, from laboratories in Japan [Nakane et (2)], describe the production of XPA-gene-deficient transgenic mice with increased susceptibility to ultraviolet-B and chemical carcinogen-induced skin tumors.
METHODS
Experimental Approach. In generating these transgenic models, homologous recombination of embryonic stem (ES) cell techniques were used. Nakane's group in Japan disrupted the XPA allele by insertion of neomycin cassette sequences into exon 4 of the XPA gene (4), and the group in The Netherlands deleted exons 3 and 4 and replaced them with neomycin cassette sequences driven by a phosphoglycerate kinase promoter (2) . Heterozygous (XPA+/-) animals were intercrossed to obtain the homozygous (XPA-/-) XPA-deficient animals. Disruption of exon 4 of the XPA gene did not result in increased embryonic lethality or physical abnormality in the offspring. However, embryonic lethality attributed to severe anemia was observed in approximately 50% of embryos with deletion of exons 3 and 4. In those surviving offspring with deletions of exons 3 and 4, no physical abnormalities were observed. Background Strains. In the Japanese study, embryonic stem cells were derived from F, hybrids of CBA and C57BL/6 mouse strains. Homologous recombinant ES cells were injected into blastocysts of CD-1 mice and implanted into pseudopregnant CD-1 foster mothers. Chimeric mice were bred with CD-1 females and offspring were intercrossed to produce homologous XPA-deficient mice (4) . In the study in The Netherlands, gene-targeted ES cells were injected into C57BL/6 blastocysts. Chimeric mice were bred with C57BL/6 mice and offspring were intercrossed to produce homozygous XPA-deficieni mice (2) .
Biological and Clinical Characteristics. To determine the XPA genotype of the offspring, Southern blot analysis of digested DNA from mouse tail tip was hybridized witt mouse XPA cDNA. Additionally, western blot analysis of splenocyte extracts to anti-XPA protein were cons protein. Primary fibroblasts isolated from XPA homozygous (XPA/-), heterozygous (XPA+/-), and wild-type (XPA+/+) embryos or newborn mice were assayed for survival and unscheduled DNA synthesis (UDS) after exposure to UV (254 nm) irradiation or treatment with the carcinogen dimethyl-benz-anthracene (DMBA) (2) . At different doses for each study [0.3-0.4 JM-2 (4), 4 Jm-Z (2)] of UV, XPA-/-fibroblast survival was approximately 10%, whereas that of +/-and +/+ was virtually 100%. UDS measured by 3H thymidine incorporation and autoradiography was barely detectable in XPA-/-cultured fibroblasts after UV exposure in both studies and following DMBA (10 /-1g once weekly; skin painting) exposure in one study.
RESULTS AND DISCUSSION
Clinically, in vivo exposure of XPA-/-mice to daily doses of UV-B (2 to -310 Jm-2) for 1-2 wk produced erythema, hyperkeratosis, and ulceration of the exposed skin of the ears and shaved backs. Similarly, weekly applications of DMBA for 2 wk to XPA-/-mice resulted in excessive hair loss and crust formation at the site of application. Continued exposure of XPA-/mice to UV-B resulted in grossly visible skin tumors after 20-25 wk. The tumors were characterized as rapidly growing and occurring in areas thatwere previously erythemic and hyperkeratotic. In one study (2) XPA-/mice developed eye lesions consisting of corneal opacities and Bowenoid lesions of the cornea after 6 wk of UV-B exposure. Similarly, skin tumors appeared in DMBA-treated XPA-/-mice as early as 6 wk, whereas skin tumors did not develop in XPA+/or XPA+/+ during the same time period or developed later (> 14 wk).
Skin Tumor Histomorphology
The earliest histological changes observed in the skin of UV-B-irradiated or DMBA-treated XPA-/-mice correlating with areas of hyperkeratosis seen grossly were acanthosis, hyperkeratosis, and hyperplasia of the epidermis and hair follicles. Histologically skin tumors in UV-B-irradiated XPA-/mice all were characterized as squamous cell carcinomas and those of DMBA-treated XPA-/mice were diagnosed as papillomas. XPA+/or XPA+/+ transgenic mice did not develop significant skin lesions during similar UV-B irradiation exposure periods.
Relevance to Human Disease
The XPA-deficient transgenic mouse provides a unique animal model of the human xeroderma pigmentosum Group A condition. The model provides key information pertaining to the expression and function of the XPA gene, nucleotide-excision repair mechanisms, cellular events in DNA damaged cells, and pathogenesis and progression of neoplastic skin cells. The study of these animals may also provide valuable insight and broaden our knowledge of the pathogenesis of experimental and spontaneous squamous cell carcinomas and nonviral papillomas of the skin. In addition, XPA-deficient transgenic mice provide an excellent model to explore and develop therapeutic strategies for XP-afflicted humans.
